Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study

Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study

Population pharmacokinetic studies have suggested that high polymyxin B (PMB) doses (≥30,000 IU/kg/day) can improve bacterial kill in carbapenem-resistant Gram-negative bacteria (CR-GNB). We aim to describe the efficacy and nephrotoxicity of patients with CR-GNB infections prescribed high-dose PMB....

Full description

Bibliographic Details
Main Authors: Yiying Cai, Hui Leck, Ray W. Tan, Jocelyn Q. Teo, Tze-Peng Lim, Winnie Lee, Maciej Piotr Chlebicki, Andrea L. Kwa
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Antibiotics
Subjects:
polymyxins
pharmacokinetics
pharmacodynamics
polymyxin B nephrotoxicity
Online Access:https://www.mdpi.com/2079-6382/9/8/451

Internet

https://www.mdpi.com/2079-6382/9/8/451

Similar Items